Embecta Corp. EMBC
6.19 USD -0.14 (-2.21%)
At closeNov 6, 2026, 4:01 PM EST
6.19 0.00 0.00%
After hours · Nov 6, 4:01 PM ET
5.78 Day range 6.38
2.77 52-week range 14.91
- YTD
- -47.90%
- 1 year
- -54.01%
- Market cap
- 350.72M
- Revenue (ttm)
- 1.11B
- Profit margin
- 5.25%
- EPS (ttm)
- 1.47
- Shares out
- 58.13M
- P/E ratio
- 4.21
- Forward P/E
- 5.95
- Dividend
- 0.60 (4.47%)
- Ex-dividend date
- Feb 27, 2025
- YTD return
- -47.90%
- 1-year return
- -54.01%
- Volume
- 623.12K
- Avg volume
- 1.26M
- Open
- 6.11
- Previous close
- 6.33
- Day's range
- 5.78 – 6.38
- 52-week range
- 2.77 – 14.91
- Beta
- 1.15
- Price target
- 22.00 (+255.4%)
- Earnings date
- Nov 26, 2024
5D -0.31 (-4.77%)
Key statistics
- Enterprise value
- 2.16B
- PEG ratio
- 0.00
- Price / sales
- 0.71
- Price / book
- 0.00
- Dividend yield
- 4.47%
- Payout ratio
- 60.61%
- Revenue growth
- -5.60%
- Free cash flow
- -37.41M
- Total cash
- 210.00M
- Total debt
- 1.59B
- Return on equity
- 0.00%
- Short % of float
- 3.97%
- 50-day average
- 18.31
- 200-day average
- 15.47
Analyst view
Price target (mean) 22.00 +255.4% upside
Now 6.19
- Target (low)
- 20.00
- Target (mean)
- 22.00
- Target (high)
- 26.00
Ratings (0m) 4 1 buy · 2 hold · 1 sell
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell1
Next earnings
Nov 26, 2024
Expected Nov 26, 2024. Consensus EPS estimate 0.5875.
Financials — quick view
EMBC Revenue — quarterly 271.70M
EMBC Net income — quarterly 21.10M
EMBC EPS — quarterly 0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 6, 2025 | Dec 1, 2024 | 0.45 | 0.65 | +0.20 | +44.44% |
| Nov 26, 2024 | Sep 1, 2024 | 0.40 | — | — | — |
| Nov 26, 2024 | Sep 1, 2024 | 0.40 | 0.45 | +0.05 | +12.50% |
| Aug 9, 2024 | Jun 1, 2024 | 0.48 | 0.74 | +0.26 | +54.17% |
| Aug 9, 2024 | Jun 1, 2024 | 0.48 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.43 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | BTIG | up | Neutral | Buy |
| Jul 15, 2024 | Morgan Stanley | main | Underweight | Underweight |
| May 10, 2024 | Morgan Stanley | main | Underweight | Underweight |
| Nov 22, 2023 | Morgan Stanley | main | Underweight | Underweight |
| Oct 18, 2023 | Morgan Stanley | main | Underweight | Underweight |
| Aug 24, 2023 | Morgan Stanley | main | Underweight | Underweight |
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- embecta.com
News
12 Health Care Stocks Moving In Friday's Intraday Session 
Embecta Raises FY2026 Adj EPS Guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 Est; Affirms FY2026 Sales Guidance of $1.015B-$1.035B vs $1.021B Est 
B of A Securities Maintains Underperform on Embecta, Lowers Price Target to $3 
Mizuho Maintains Neutral on Embecta, Lowers Price Target to $5 
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Earnings Scheduled For May 5, 2026 
Embecta Lowers FY2026 Adj EPS Guidance from $2.80-$3.00 to $1.55-$1.75 vs $2.81 Est; Lowers FY2026 Sales Guidance from $1.071B-$1.093B to $1.015B-$1.035B vs $1.071B Est
Your note
Sign in to keep a note on EMBC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALBRITTON DAVID | Director | Stock Award(Grant) | Feb 11, 2025 | 39,743 |
| ANDERSON CARRIE L | Director | Stock Award(Grant) | Feb 11, 2025 | 39,743 |
| CASNER JEAN | Officer | Stock Award(Grant) | Nov 25, 2024 | 48,288 |
| HOMBACH ROBERT J. CPA | Director | Stock Award(Grant) | Feb 11, 2025 | 39,749 |
| MELCHER DAVID F. | Director | Purchase | Feb 24, 2025 | 76,681 |
| MORRIS MILTON MAYO | Director | Sale | Feb 12, 2025 | 36,133 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.01% | 9,305,878 | 125.63M | Dec 30, 2024 |
| Vanguard Group Inc | 12.08% | 7,025,483 | 94.84M | Dec 30, 2024 |
| Deerfield Management Company, L.P. (Series C) | 5.63% | 3,270,535 | 44.15M | Dec 30, 2024 |
| American Century Companies Inc | 5.61% | 3,261,934 | 44.04M | Dec 30, 2024 |
| River Road Asset Management, LLC | 5.59% | 3,247,389 | 43.84M | Dec 30, 2024 |
| FMR, LLC | 4.29% | 2,491,123 | 33.63M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 6.47% | 3,758,570 | 50.74M | Dec 30, 2024 |
| American Century Small Cap Value Fund | 4.18% | 2,430,000 | 32.80M | Dec 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.28% | 1,907,344 | 25.75M | Sep 29, 2024 |
| Fidelity Low-Priced Stock Fund | 2.88% | 1,676,327 | 22.63M | Oct 30, 2024 |
| AMG Yacktman Fd | 2.75% | 1,600,000 | 21.60M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.67% | 1,554,650 | 20.99M | Dec 30, 2024 |